Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa JKN2304 inhalation solution in moderate-to-severe COPD
CTR20252560Phase 2Completed
- Sponsor
- Beijing Shuobai Pharmaceutical Technology
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JKN2304 in chronic obstructive pulmonary disease (COPD), sponsored by Beijing Shuobai Pharmaceutical Technology. Started Jun 2025; status: completed.
02
Drugs
JKN2304
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20252560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252560.